Ten Critical Ethical, Conceptual, and Clinical Cautions Concerning the Diagnosis and Treatment of Gender Dysphoria and Transgender Identification

Abstract

There is an urgent need for ethical, conceptual, and clinical clarity regarding the diagnosis and treatment of gender dysphoria and transgender identification. In this essay, I highlight ten critical concerns in this arena, namely, those involving: (1) conceptual parallels between sexual reassignment surgery and elective limb amputation; (2) the lack of long-term data that demonstrates reliable long-term relief from gender dysphoria in those undergoing hormonal or surgical treatment for gender dysphoria; (3) special problems with informed consent in the context of “gender affirming” treatments; (4) the importance of very high desistance rates of gender dysphoria and transgender identification, particularly in children, even without treatment; (5) the extensive differential diagnosis and the need for thorough and subtle assessments in the face of gender-related complaints; (6) a deep religiously based objection to transgender ideology involving the ordering of creation; (7) controversies concerning the existence of rapid-onset gender dysphoria; (8) the recent depathologizing of gender dysphoria; (9) the roles of genetics and environment in transgender identification and gender dysphoria; and (10) reflections on the role of psychotherapeutic treatment in patients with gender dysphoria and transgender identification.

Keywords: transgenderism, gender dysphoria, transsexualism, sexual reassignment surgery, gender affirming care

Does the Use of Puberty-Suppressing Drugs Satisfy the Requirements of Informed Consent?

Abstract

Gonadotropin-releasing hormone analogs (“puberty blockers”) have rapidly become the preferred method of treatment for childhood gender nonconformity or for teenagers experiencing various levels of gender dysphoria. Use of these drugs raises questions regarding the ability of prepubescent children to give an informed consent to life-altering interventions with unknown future effects. The article argues the use of puberty blockers fails to meet the standard of informed consent.

Keywords: Gonadotropin-Releasing Hormone Analogs, Puberty Blockers, Informed Consent, Gender Affirmative Model.